1Stanescu D. Sanna A. Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers areassociated with increased levels of sputum neutrophils. Thorax, 1996,51 : 267 - 271.
2Noguera A, Bnsquets X, Sauleda J, et al. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstruc- tive pulmonary disease. Am J Respir Crit Care Med, 1998, 158 (5 Pt 1):1 664-1 668.
3Noguera A, Sala E, Pons AR, et al. Expression of adhesion molecules during apoptosis of circulating neutrophils in COPD. Chest, 2004,125:1 837- 1 842.
4Sauleda J, Garcia - Palmer FJ, Gonzalez G, et al. The activity of cytochrome oxidase is increased in circulating lymphocytes of patients with chronic obstructive pulmonary disease, asthma, and chronic art hritis. Am J Respir Crit Care Med,2000,161 : 32 - 35.
5Miller L G, Goldstein G, Murphy M, et al. Reversible alterationsin immunoregulatory T cells in smoking. Analysis by monoclonal antibodies and flow cytomet ry. hest, 1982,82: 526 - 529.
6Agust la GN,Noguera A.Sauleda J, et al. Systemic inflammationin chronic respiratory diseases. Eur Respir J, 2003,21 : 347 - 360.
7Dentener MA,Creuzberg EC,Schols AMWJ, et al. Systemic anti -inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax, 2001,56:721 - 726.
8Rahman I,Swarska E,Henry M, et al. Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease.? Thorax,2000, 55 : 189 - 193.
9Noguera A, Batle S, Miralles C, et al. Enhanced neutrophilresponse in chronic obstructive pulmonary disease. Thorax, 2001,56:432-437.
10Nowak Nowak D, Kasielskim M,Antczak A, et al. Increased content of thiobarbituric acid - reactive substances and hydrogen peroxide int heexpired breath condensate of patients with stable chronic obstructive pulmonary disease : no significant effect of cigarette smoking. Respired, 1999,93 : 389 - 396.
4Martin-Ventura J L, Blanco-Colio L M, Gomez-Hernandez A, et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month[J]. Stroke, 2005, 36(8) : 1796 -1800.
5Borchers M T, Wert S E, Leikauf G D. Acrolein-induced MUC5ac expression in rat airways[J]. Am J Physiol, 1998, 274(4 Pt 1 ) : L573 - L581.
6Borchers M T, Wesselkamper S, Wert S E, et al. Monocyte inflammation augments acrolein-induced Muc5ac expression in mouse lung[J]. Am J Physol, 1999, 277(3 Pt 1) : L489 - L497.
7McKay A, Leung B P, McInnes I B, et al. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma [J].J Immunol, 2004, 172(5) : 2903 -2908.
3] Groenewegen KH,Dentener MA,Wouters EF. Longitudinal follow-up of systemic inflammation after acute exacerbations of COPD [J]. Respir Med, 2007,101 - 11 - : 2409-2415.
4Tumkaya M,Atis S,Ozge C,et al. Relationship between airway colonization, inflammation and exacerbation frequency in COPD [J]. Respir Med, 2007,101(4- :729-737.
5Sncini GB, Etminan M. Zhang B, et al. Reduction of morbidity and mortality by statins. Angiotensln-conveaing enzyme inhibitors.and angiotensin receptor blockers in patients with chronic obstructive- disease [J]. J Am Coll Cardiol, 2006, 47(12): 2554-2560.
6Rost FJ, Petersen H, Tollestrnp K, et al. Influenza and COPD mor-tality protection as pleiotrnpic dose-dependent effects of statios [J]. chest, 2007, 131(4): 1006-1012.
7Eyseth V, Brekke P, Smith P, et al. Statin use is associatewith reduced mortality in COPD [J]. Eur Respir J, 2007, 29(2): 279-283.
8MaeNee W. Update in chronic obstructive pulmonary disease 2007[J]. Am J Respir Crit Care Med, 2008, 177(8): 820-829.
